Cover Image
Market Research Report

Global Impetigo Treatment Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 756702
Published Content info 104 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Impetigo Treatment Market 2019-2023
Published: November 28, 2018 Content info: 104 Pages
Description

About this market:

The evolving resistance of microorganisms is likely to push growth in the market. There has been evolving resistance owing to the frequent usage of oral antibiotics. Hence manufacturers are developing more effective antibiotics to treat skin infections. Technavio's analysts have predicted that the impetigo treatment market will register a CAGR of about 7% by 2023.

Market Overview:

Low cost of treatment

Impetigo is a common, highly contagious bacterial skin infection. However, the infection can be treated easily without spending much.

Side effects of drugs

Impetigo is a bacterial infection of the skin which is treated with topical antibiotics or oral drugs. However, few side effects of these drugs may pose a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the impetigo treatment market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Cutanea Life Sciences and GlaxoSmithKline the competitive environment is quite intense. Factors such as the low cost of treatment and the low cost of treatment, will provide considerable growth opportunities to impetigo treatment manufactures. Cutanea Life Sciences, GlaxoSmithKline, LEO Pharma, and Medimetriks Pharmaceuticals are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.'

Table of Contents
Product Code: IRTNTR30257

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Topical - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: SEGMENTATION BY DRUG CLASS

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Market trends

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Cutanea Life Sciences
  • GlaxoSmithKline
  • LEO Pharma
  • Medimetriks Pharmaceuticals

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations

PART 17: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global dermatological drugs market
  • Exhibit 02: Segments of global dermatological drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Topical - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Topical - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Key leading countries
  • Exhibit 34: Market opportunity
  • Exhibit 35: Impact of drivers and challenges
  • Exhibit 36: Vendor landscape
  • Exhibit 37: Landscape disruption
  • Exhibit 38: Vendors covered
  • Exhibit 39: Vendor classification
  • Exhibit 40: Market positioning of vendors
  • Exhibit 41: Cutanea Life Sciences - Vendor overview
  • Exhibit 42: Cutanea Life Sciences - Organizational developments
  • Exhibit 43: Cutanea Life Sciences - Key offerings
  • Exhibit 44: GlaxoSmithKline - Vendor overview
  • Exhibit 45: GlaxoSmithKline - Business segments
  • Exhibit 46: GlaxoSmithKline - Organizational developments
  • Exhibit 47: GlaxoSmithKline - Geographic focus
  • Exhibit 48: GlaxoSmithKline - Segment focus
  • Exhibit 49: GlaxoSmithKline - Key offerings
  • Exhibit 50: LEO Pharma - Vendor overview
  • Exhibit 51: LEO Pharma - Organizational developments
  • Exhibit 52: LEO Pharma - Geographic focus
  • Exhibit 53: LEO Pharma - Key offerings
  • Exhibit 54: Medimetriks Pharmaceuticals - Vendor overview
  • Exhibit 55: Medimetriks Pharmaceuticals - Organizational developments
  • Exhibit 56: Medimetriks Pharmaceuticals - Key offerings
Back to Top